Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...

The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...

Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Eli Lilly and artificial intelligence (AI)-focused Genetic Leap have entered into a research collaboration worth up to $409m to develop genetic medicines. The partnership will see the companies use ...